Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Marizyme Inc (EM) MRZM

Healthcare Biotechnology
Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery. Its product portfolio includes DuraGraft, a... see more

Current News (EXPM:MRZM)

Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme

GlobeNewswire April 1, 2025

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)

GlobeNewswire April 16, 2024

Marizyme CEO Delivers Business Update

GlobeNewswire October 23, 2023

Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft(TM)

GlobeNewswire October 6, 2023

Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products

GlobeNewswire May 10, 2023

Marizyme CEO Delivers Business Update

GlobeNewswire May 3, 2023

Statera Biopharma Announces Changes to Board of Directors

GlobeNewswire February 25, 2022

Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office

GlobeNewswire January 5, 2022

Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing

GlobeNewswire December 23, 2021
View More News ››

Opinion & Analysis (EXPM:MRZM)

Revolutionizing vascular grafting with a durable solution

Brieanna McCutcheon  September 27, 2023
View More Opinion ››

Bullboard Posts (EXPM:MRZM)

Three stocks to buy right now and hold forever

https://themarketherald.ca/three-stocks-to-buy-right-now-and-hold-forever-2023-10-06/
TrevorAbes - October 6, 2023
View more Bullboard ››

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »

Podcasts